Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual treatments with the substances.
This time, Incannex Healthcare IXHL has placed a purchase order for the Toronto-based company’s proprietary MDMA “LaNeo” as well as psilocybin to be used in several planned clinical studies.
The agreement follows Melbourne, Australia-based Incannex’s announced plans to create a subsidiary to work with the country on legalizing MDMA for PTSD treatment and psilocybin for that of Treatment-Resistant Depression.
The new company would open a first “model” clinic providing the mentioned psychedelic-assisted therapies sometime this year.
Meanwhile, Incannex holds an ongoing Phase 2a clinical trial on psilocybin-assisted therapy for Generalized Anxiety Disorder.
On behalf of PharmAla, the company recently partnered with also psychedelics business Mindset Pharma MSSTF to supply clinical-grade psilocybin to Little Green Pharma’s subsidiary Reset Mind Sciences Ltd. for a clinical trial on patients with treatment-resistant, Major Depressive Disorder.
Additionally, PharmAla provided its MDMA to Australian company Emyria Ltd. for research purposes, and further submitted a national trademark application for LaNeo as well as the company’s brand name including both EU-GMP MDMA and EU-GMP psilocybin products.
ICYMI: Exclusive Coverage From the Benzinga Psychedelics Capital Conference 2023:
Photo: Benzinga edit with photo by PublicDomainPictures and sergeitokmakov on Pixabay.